These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14996627)

  • 41. Aromatase inhibitors in the treatment of breast cancer.
    Brueggemeier RW; Hackett JC; Diaz-Cruz ES
    Endocr Rev; 2005 May; 26(3):331-45. PubMed ID: 15814851
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
    Lønning PE
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
    Baumann ChK; Aebi S
    Ther Umsch; 2004 Jun; 61(6):359-64. PubMed ID: 15253160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
    Herold CI; Blackwell KL
    Clin Breast Cancer; 2008 Feb; 8(1):50-64. PubMed ID: 18501059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
    Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
    Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are differences in the available aromatase inhibitors and inactivators significant?
    Johnson PE; Buzdar A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y; Simondsen K; Kolesar JM
    Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial.
    Baum M
    Cancer Control; 2004; 11(4):217-21. PubMed ID: 15284712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
    Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aromatase inhibitors versus tamoxifen for management of postmenopausal breast cancer in the advanced disease and neoadjuvant settings.
    Ingle JN; Suman VJ
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):313-9. PubMed ID: 14623527
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
    Colozza M; Califano R; Minenza E; Dinh P; Azambuja E
    Mini Rev Med Chem; 2008 Jun; 8(6):564-74. PubMed ID: 18537711
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aromatase inhibitors.
    Cunnick GH; Mokbel K
    Curr Med Res Opin; 2001; 17(3):217-22. PubMed ID: 11900315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exemestane in advanced breast cancer.
    Buzdar A
    Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention.
    Ingle JN
    Oncology (Williston Park); 2001 May; 15(5 Suppl 7):28-34. PubMed ID: 11396362
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aromatase inhibitors in breast cancer therapy.
    Brueggemeier RW
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exemestane: treatment of breast cancer with selective inactivation of aromatase.
    Higa GM
    Am J Health Syst Pharm; 2002 Nov; 59(22):2194-2201; quiz 2202-4. PubMed ID: 12455303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.